Bristol-Myers Squibb and Five Prime Therapeutics to evaluate combination of Opdivo (nivolumab) and FPA008 in six tumor types
24 November 2014 | By Bristol-Myers Squibb
Bristol-Myers Squibb and Five Prime Therapeutics have announced exclusive clinical collaboration to evaluate the combination of investigational immunotherapies Opdivo (nivolumab) and FPA008 in six tumor types...